Figure 2.
Figure 2. Cumulative incidences of (A) graft rejection, (B) developing acute grade II–IV GVHD in patients with aplastic anemia given HLA-identical marrow grafts following CY/ATG and GVHD prophylaxis with MTX/CSP, (C) prevalence of chronic GVHD, and (D) probability of survival among the 29 patients with chronic GVHD and probability of discontinuing immunosuppression given for chronic GVHD. / Reprinted with permission from Storb R, Blume KG, O’Donnell MR, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic transplantations: the experience in four centers. Biol Blood Marrow Transplant. 2001;7:39–44.

Cumulative incidences of (A) graft rejection, (B) developing acute grade II–IV GVHD in patients with aplastic anemia given HLA-identical marrow grafts following CY/ATG and GVHD prophylaxis with MTX/CSP, (C) prevalence of chronic GVHD, and (D) probability of survival among the 29 patients with chronic GVHD and probability of discontinuing immunosuppression given for chronic GVHD.

Reprinted with permission from

Storb R, Blume KG, O’Donnell MR, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic transplantations: the experience in four centers. Biol Blood Marrow Transplant. 2001;7:39–44.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal